Cynosure Group LLC Has $905,000 Position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

Cynosure Group LLC cut its stake in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 24.9% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 10,841 shares of the biopharmaceutical company's stock after selling 3,601 shares during the period. Cynosure Group LLC's holdings in Intra-Cellular Therapies were worth $905,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. The Manufacturers Life Insurance Company raised its holdings in shares of Intra-Cellular Therapies by 1.3% in the third quarter. The Manufacturers Life Insurance Company now owns 22,057 shares of the biopharmaceutical company's stock valued at $1,614,000 after buying an additional 283 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of Intra-Cellular Therapies by 13.2% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 22,522 shares of the biopharmaceutical company's stock worth $1,648,000 after purchasing an additional 2,622 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in shares of Intra-Cellular Therapies by 3.6% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 323,208 shares of the biopharmaceutical company's stock valued at $23,649,000 after buying an additional 11,104 shares during the period. Captrust Financial Advisors increased its position in shares of Intra-Cellular Therapies by 47.0% in the 3rd quarter. Captrust Financial Advisors now owns 8,050 shares of the biopharmaceutical company's stock valued at $589,000 after buying an additional 2,572 shares in the last quarter. Finally, Erste Asset Management GmbH acquired a new stake in Intra-Cellular Therapies during the 3rd quarter worth $1,715,000. 92.33% of the stock is owned by institutional investors and hedge funds.

Intra-Cellular Therapies Stock Performance

Shares of NASDAQ ITCI remained flat at $131.87 during mid-day trading on Monday. Intra-Cellular Therapies, Inc. has a 12-month low of $64.09 and a 12-month high of $131.98. The firm's 50-day simple moving average is $129.62 and its 200 day simple moving average is $101.80. The stock has a market cap of $14.05 billion, a P/E ratio of -151.57 and a beta of 0.69.

Intra-Cellular Therapies (NASDAQ:ITCI - Get Free Report) last announced its quarterly earnings data on Friday, February 21st. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.08) by ($0.08). Intra-Cellular Therapies had a negative return on equity of 9.93% and a negative net margin of 14.07%. The firm had revenue of $199.22 million for the quarter, compared to analyst estimates of $205.08 million. On average, sell-side analysts anticipate that Intra-Cellular Therapies, Inc. will post -0.64 EPS for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on ITCI shares. Baird R W downgraded Intra-Cellular Therapies from a "strong-buy" rating to a "hold" rating in a report on Monday, January 13th. Canaccord Genuity Group downgraded shares of Intra-Cellular Therapies from a "buy" rating to a "hold" rating and increased their price objective for the stock from $119.00 to $132.00 in a research report on Friday, January 31st. Royal Bank of Canada reaffirmed a "sector perform" rating and issued a $132.00 price objective (up from $108.00) on shares of Intra-Cellular Therapies in a research report on Wednesday, January 22nd. Piper Sandler reiterated a "neutral" rating and set a $132.00 target price (up previously from $107.00) on shares of Intra-Cellular Therapies in a report on Tuesday, January 14th. Finally, Leerink Partnrs lowered Intra-Cellular Therapies from a "strong-buy" rating to a "hold" rating in a report on Monday, January 13th. Eleven equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Hold" and an average target price of $106.23.

About Intra-Cellular Therapies

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.